October 2017 Issue Table Of Contents
Source: Life Science Leader

From The Editor
Feature Articles
- Can David Hung Lead Axovant To Alzheimer’s Success?
- Can We Make Innovative Medicines Affordable?
- PROMETIC: New Tech Harvests Orphan Treatments
Capitol Perspectives
Companies To Watch
CEO Corner
Inside The Industry
- Importing Canadian Drugs Won’t Solve U.S. Pricing Concerns
- Value-Based Healthcare: Pharma’s Role In The Transition
- Why South Korea Is The Hottest Growth Spot For Clinical Trials
- Diversification Relieves Funding Pressure For Small Pharma
- Fostering Innovation Through A Diverse Workforce In Biotech
- A Name Change — And More — For A Biotech
- After The Failed Trans-Pacific Partnership: What Comes Next?
- Can AI Deliver Faster, Better Drug Development?
Leadership Lessons
Ask The Board
- What Are Your Thoughts On The New FDA Commissioner’s (Scott Gottlieb) Proposal To Make Generic Drug Approval Easier, And Do You Agree That The Impact Will Be A Lowering Of Drug Pricing?
- What’s Next In Processes And Facilities?
- What Are You Doing To Address Some Of The Common Challenges Confronting The Industry (E.G., Industry Image, Clamor For Government Intervention)?
This website uses cookies to ensure you get the best experience on our website. Learn more